News
Home  >  News > Spin-off Reveal Genomics to commercialize a genetic test to customize breast...

Spin-off Reveal Genomics to commercialize a genetic test to customize breast cancer treatment

 

 

26/01/2022

Recerca

Reveal Genomics, a spin-off created by the University of Barcelona, Hospital Clínic de Barcelona and the Vall d'Hebron Institute of Oncology, will commercialize HER2DX. This test predicts the prognostic of patients with HER2 positive breast cancer patients (HER2+) in early stages, as well as the probability of patients to respond to given pharmacological treatments before the tumour surgery.


Further information

 

 

 

Share this at:
| More |
  • Follow us:
  • Button to access University of Barcelona's Facebook profile
  • Button to access University of Barcelona's Twitter profile
  • Button to access University of Barcelona's Instagram profile
  • Button to access University of Barcelona's Linkedin profile
  • Button to access University of Barcelona's Youtube profile
  • Button to access University of Barcelona's Google+ profile
  • ??? peu.flickr.alt ???
Member of International recognition of excellence HR Excellence in Research logo del leru - League of European Research Universities logo del bkc - campus excel·lència logo del health universitat de barcelona campus

© Universitat de Barcelona